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Abstract
We examined the relationship between non-invasive
estimates of the tumor hemoglobin concentration by
near- infrared spectroscopy (NIRS) and histological
scores of tumor vascularity by Chalkley counts in seven
tumor lines in nudemice [malignant gliomas: U87, U118,
U373; small cell lung cancers (SCLC): 54A, 54B, DMS79;
prostate cancer: MatLyLu (MLL)]. We also evaluated the
effect of continuous anti -angiogenic treatment with
TNP-470 on tumor hemoglobin concentration and
tumor vascularity in U87 and MLL tumors. Non-invasive
NIRS recordings were performed with a custom-built
flash near- infrared spectrometer using light guide–
coupled reflectance measurements at 800±10 nm.
Chalkley counts were obtained from CD31-immunos-
tained cryosections. The NIRS recordings in arbitrary
absorbance units increased with tumor size in the
individual tumors until a plateau was reached at
approximately 150 mm3. This plateau was relatively
tumor line–specific. NIRS recordings at the plateau
phase were strongly correlated (P<.001, n=71) to the
histological vessel score (Chalkley count) of the same
individual tumors excised immediately after the NIRS
was performed. Non-invasive NIRS recordings of the
highly vascularized gliomas (U87, U118, and U373) plus
the MatLyLu tumor line were significantly higher than
the three less vascularized SCLC tumor lines (P<.001).
Continuous treatment with the anti -angiogenic com-
pound TNP-470, an endothelial cell inhibitor, signifi-
cantly retarded tumor growth in both U87 and MLL
tumors, but all tumors eventually grew. When compar-
ing treated and untreated tumors of similar size, both
NIRS recordings and Chalkley counts were significantly
lower in TNP-470–treated tumors (P<.05). In conclu-
sion, the NIRS technique provides a non- invasive
measure of the degree of vascularization in untreated
tumors and the NIRS technique can measure modifica-
tions in tumor vascularization by anti -angiogenic
therapy. Neoplasia (2001) 3, 324–330.
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Introduction
Assessment of angiogenic activity in tumors is most often
obtained by histological examination using immunohisto-
chemical markers of endothelium [1]. This approach requires
removal of tissue material, and the information is two-
dimensional. In spite of such limitations, the prognostic value
of histological estimates of tumor angiogenesis is well
documented, especially by the Chalkley count method [2–
4]. This method determines the vessel content in immunos-
tained cryosections as the relative area of the immunostained
vessels expressed by an index without unit. The interobser-
vational contribution to the methodological variation tends be
relatively low [2]. The underlying assumption is that the
vascularity reflects the intensity of tumor angiogenesis and
represents the tumor- to-blood exchange capacity of the
tissue.
Because hemoglobin is a strong absorber of near- infrared
light, the near- infrared spectroscopy (NIRS) can provide
non- invasive and semi-quantitative measurements of the
total hemoglobin concentration. At 800 nm (the isosbestic
point of hemoglobin), the light absorption of a tissue is
proportional to the total hemoglobin concentration, disturbed
only marginally by other chromophores of the tissue [5,6 ].
The total hemoglobin concentration reflects the blood volume
because the source of hemoglobin is the red blood cells.
Near- infrared light has longer wavelength than visible light,
and therefore, its absorption in water is less, which allows
monitoring of deeper tissue regions due to greater tissue
penetration.
A correlation between hemoglobin concentration in exper-
imental tumor xenografts determined by non- invasive NIRS
and the histomorphological tumor vascularity determined by
histological examination has not previously been established.
A recent pilot study reported hemoglobin concentration maps
from a series of normal breasts, plus one fibroadenomatous
breast and a single breast tumor. Their hemoglobin-weighed
images were reconstructed on the basis of shine- through
NIRS [7].
The hemoglobin concentration measured by biochemical
methods and the vessel density determined by histological
examination were earlier shown to be well correlated in
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biocompatible implant models containing angiogenic factors
[8 ]. In a recent study, we showed that NIRS could detect
angiogenic and anti -angiogenic activity in a simple subcuta-
neous bFGF pellet implantation model [9].
The efficacy of anti -angiogenic therapy has been demon-
strated using different inhibitors of angiogenesis in numerous
tumor models [10,11]. Anti -angiogenic therapy has been
reported to decrease the vascular density determined by
histological examination [12,13]. However, in such studies,
relatively small, treated tumors are oftenmatched with larger,
control tumors because all the tumors are scored at the same
time point, namely when the control tumors reached their
maximal size. In this situation, it is difficult to exclude that the
reduced vascularization is a consequence, rather than the
cause, of the smaller size of the tumors.
We examined the relationship between non- invasive
NIRS and Chalkley counts in seven tumor lines, and
evaluated the effect of continuous anti -angiogenic therapy
with TNP-470 on these parameters in the highly vascular-
ized U87 and MLL tumors. We found that NIRS recordings
and Chalkley counts of the individual tumors were strongly
correlated, suggesting that NIRS provides a non- invasive
estimate of the degree of vascularization in tumors.
Continuous anti -angiogenic therapy with TNP-470 signifi-
cantly reduced the NIRS recordings and Chalkley counts in
U87 and MLL tumors of similar size, demonstrating that the
NIRS technique can measure modifications of tumor
vasculature during anti -angiogenic therapy.
Materials and Methods
Animals
Male 8-week-old athymic nude mice (NMRI-nu/nu)
obtained from M&B (Ry, Denmark) were used. The mice
were kept in groups of five in laminar airflow benches and
were fed sterile food pellets and water ad libitum. Institutional
guidelines for animal welfare and experimental conduct were
followed. Prior to implantation or NIRS measurements, the
animals were anaesthetized with ketamine/xylazine (10 per
100 mg/kg s.c. ).
Tumor
Seven tumor lines were examined: three human malig-
nant glioma lines (U87, U118, U373) obtained from
American Tissue Culture Collection (ATCC, Rockville,
Maryland), three human small cell lung cancer (SCLC) lines
(54A, 54B) established here [14] and DMS79 obtained from
Dartmouth Medical School (Hanover, New Hampshire) [15],
and finally one rat prostate cancer line (MatLyLu) kindly
donated by Dr. Z. Bhujwalla (Johns Hopkins University,
Baltimore, Maryland). The SCLC lines were included
because of their relatively low vascularity, as shown
previously [16], whereas the glioma lines and the MatLyLu
were selected for this study because of their high angiogenic
activity.
An incision of 1 cm was made though the skin
approximately 2 cm from the hind leg and a small tumor
block was tunneled to its destination subcutaneously on the
hind leg. The hind leg was used due to good fixation of the
tumor inocula and lack of interference by respiratory
movements during the NIRS recordings. Animals were
sacrificed when the tumor reached a size of approximately
400 mm3, and the tumors were excised for histological
examination.
Growth Calculation
The subcutaneous tumor size was measured in two
perpendicular dimensions (d1 and d2) using a slide gauge,
and the tumor volume curves, V( t ), were obtained according
to the following formula:
VðtÞ ¼ 0:35ðd1ðtÞ  d2ðtÞÞ3=2
The time until initiation of exponential growth of the
individual tumors was determined from individual volume
curves plotted semi- logarithmically, as previously described
[17]. In short, the time until initiation of exponential tumor
growth was determined as the intersection between the
best- fitting line depicting the early lag phase and the linear
regression line during the exponential growth phase. The
validity of this simplification was documented by high
correlation coefficients (R2=0.956±0.039, mean±SD).
The tumor doubling time was derived from the linear
regression line during the exponential growth phase.
Anti -Angiogenic Treatment
Leo Pharmaceutical Products (Ballerup, Denmark)
generously provided TNP-470 (O -chloroacetyl carbamoyl
fumagillol ). A stock solution of 70% ethanol and TNP-
470, 10 mg/mL, was prepared and stored at 48C.
Immediately prior to treatment, the stock solution was
diluted with 0.9% NaCl to obtain a dosing concentration
of 1 mg/mL. TNP-470 30 mg/kg 3 /week or 7 mg/kg
Figure 1. Gross appearance and representative histological examination
(100 magnification ) of a less vascularized 54B tumor line (A, B ) and a more
vascularized U87 tumor line (C, D ). Sections shown are CD31 - immunos-
tained cryosections counterstained with hematoxylin.
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4 /day was administered subcutaneously in the neck
region starting immediately after tumor implantation.
TNP-470 is a potent inhibitor of angiogenesis, which
has been shown to inhibit endothelial cell proliferation
and migration, as well as tumor growth in several in vivo
assays [17–19].
NIRS Recordings
The mice were anaesthetized 15 minutes before NIRS
recordings to eliminate artifacts from body movements. The
experiments were performed at constant room temperature
of 25±18C. A micromanipulator was used to maintain a
reproducible localization of the NIRS probe perpendicular to
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Figure 2. (A ) Example of an individual plot of repeated non - invasive NIRS recordings of a single 54B tumor during tumor growth. The NIRS recordings increased
during early tumor growth and reached a plateau from tumor sizes of 100 mm3. (B–H) Plots of the relationship between NIRS recordings and tumor volume in each
of the seven tumor lines.
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and in close contact with the skin, yet carefully avoiding
tissue compression. Recordings were made two to three
times a week and immediately before removal of the tumor
( the final NIRS recording).
The NIRS instrument was custom-built (NMR Center,
University of Copenhagen, Denmark) including a xenon
flash as the light source ( l4633 Hamamatsu, Near- Infrared
Spectrometer) and a photo diode (Siemens BPW21 photo
diode) as the light detector. Briefly, an optical filter (800±10
nm interference filter ) in front of the xenon flash unit results
in emission of light with a wavelength of 800±10 nm. A
branched light guide (Y-shaped) accomplished the cou-
pling between the instrument and the animal. Reflected light
from the tissue, i.e., the light that is not absorbed or
scattered, is transmitted through the other branch of the Y-
shaped optical fiber to a second optical filter before the
photodiode. The 800±10 nm optical filters secure detection
of light absorption of this specific wavelength area only. In
the fused end of the light guide, the emitting and trans-
mitting fibers are randomly mixed, and the diameter of that
part of the probe is 3.0 mm. An electric signal corresponding
to the light received by the photo diode is transmitted to an
amplifier and from there to a sample and hold circuit. From
the sample and hold circuit, the signal is taken out to an
analog strip chart recorder.
The NIRS instrument was calibrated before each exper-
imental session. The calibration was stable over time and the
calibration was controlled after use. Full absorption, i.e., zero
signal was set to 100 arbitrary absorbance units (ABU) and
Motility Standard (Perimed, Lund, Sweden) was calibrated
to 50 ABU. The NIRS value was calculated as the median of
five recordings.
Animals were sacrificed after the final NIRS recording,
and the tumors were excised for histological examination.
Immunohistochemistry
The excised tissue was frozen in cooled isopentane and
cryosections were obtained from the tumors. Sections were
washed in PBS and TBS and incubated with 10% rabbit
serum for 30 minutes. They were then incubated with a
mixture of two monoclonal rat anti -mouse CD31 antibodies
at a dilution of 15 g/mL overnight at 48C. The antibodies
used were clone 390 (Serotec, Oxford, UK) and MEC 13.3
(PharMigen, San Diego, CA). Rat IgG2a (Serotec) was
used as negative control. Sections were incubated with
biotin-conjugated rabbit anti -rat immunoglobulin (Dako,
Copenhagen, Denmark) at a dilution of 1:200 (1.5 g/mL)
for 30 minutes. As substrate for the alkaline phosphatase
reaction, we used freshly prepared Fast Red Substrate
System (Dako), followed by a 10-minute wash in tap water.
After this, sections were counterstained with hematoxylin
and mounted with aqueous mounting media.
Chalkley Counts
A cross-section of the tumor was examined. The ocular
Chalkley grid (Graticules, Tonbridge, UK) was rotated until
the maximal number of dots of the Chalkley point array hit on,
or within the, area of CD31-stained vessel profiles (200
magnification). The Chalkley count was calculated as the
mean of counts in 10 fields per section randomly selected
from non-necrotic areas of the tumors. Two observers
performed all Chalkley counts independently using a LEICA
DMRB microscope.
Statistical Analysis
The distribution of tumor volume and time until initiation of
exponential growth were not consistently Gaussian. There-
fore, data were shown as median value ( total range) and
80
82
84
86
88
90
92
94
96
98
100
0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0
Chalkley counts (mean of counts in 10 fields)
N
IR
S 
(A
BU
)
Figure 3. Correlation between the final NIRS recording and Chalkley count
from the same individual tumors excised immediately after the NIRS
recording. The glioma lines (U87, U373, U118 ) and the MLL had significantly
higher Chalkley counts (P< .001, t - test ) than the SCLC lines (54A, 54B,
DMS79 ). Correspondingly, the NIRS recordings of the gliomas and MLL were
significantly higher than the SCLC tumors (P< .001, t - test ). The correlation
between the Chalkley counts and the final NIRS recordings of all tumors was
strong (Spearman’s test, r S=0.77, P< .001 ). Solid diamond (U87, n=15 ),
solid triangle (U118, n=7 ), solid box (U373, n=5 ), solid circle (MLL, n=16 );
open diamond (54A, n=8 ), open triangle (DMS79, n=10 ), open box (54B,
n=10 ).
Table 1. Early Tumor Growth Characteristics of Untreated Versus TNP-470–Treated U87 and MLL Tumors Growth.
U87 MLL
Control (n=20 ) TNP -470 (n=9 ) Control (n=16 ) TNP -470 (n=13 )
Time until initiation of exponential growth ( days )* 10 (5–31 ) 26 (19–42 ) 4 ( 2–6 ) 6 ( 3–8 )
Mann -Whitney U test (P< .001 ) (P< .005 )
Tumor doubling time during exponential growth ( days )y 3.24±0.30 4.49±1.12 1.41±0.57 2.40±0.67
t - test (P< .01 ) (P< .001 )
*Median ( total range )
yMean±SD.
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statistical evaluations of differences between treated versus
untreated groups of animals were performed by a two- tailed
Mann-Whitney U test for non-parametric data.
Statistical evaluations of differences in NIRS recordings,
Chalkley counts, and tumor doubling time between treated
versus untreated groups of animals were performed using an
unpaired two- tailed t - test. These data were shown as mean
value±SD.
The correlation between NIRS recordings and Chalkley
counts was evaluated by Spearman’s rank correlation ( rS)
because no specific mathematical interrelationship was to be
expected.
Results
Figure 1 shows the gross appearance and representative
CD31- immunostained cryosections of a less vascularized
54B tumor and a more vascularized U87 tumor.
In all tumors, the 800-nm light absorbance increased
with the tumor size until a tumor-specific plateau was
reached from tumor sizes of 100 to 150 mm3, as shown in
Figure 2.
The Chalkley counts and the final NIRS recordings of the
same individual tumors were strongly correlated ( rS=0.77,
P<.001, n=71) (Figure 3 ). The NIRS recordings of the
gliomas and prostate lines were significantly higher
(P<.001) than the NIRS of the SCLC tumors. This reflected
the correspondingly higher Chalkley counts in the former
than in the SCLCs (P<.001).
Continuous treatment with the anti -angiogenic compound
TNP-470 significantly retarded tumor growth in both U87 and
MLL tumors, evaluated by time until initiation of exponential
tumor growth and by tumor doubling time after initiation of
exponential growth (Table 1). When comparing treated
versus untreated U87 and MLL tumors of similar size, the
final NIRS recordings and the Chalkley counts were signifi-
cantly lower in TNP-470–treated tumors (Figure 4 ). These
effects were tumor volume–independent because there was
no specific variation in the NIRS recordings and Chalkley
counts within the tumor volume range, and there were no
differences in the groups of tumor volumes compared.
Discussion
Our data suggest that NIRS provides a simple non- invasive
estimate of the vascular compartment of solid tumors similar
to the information obtained by the inherently destructive
histological Chalkley count analysis. This correlation is not
surprising because tissue absorbance at 800 nm is primarily
an effect of the concentration of hemoglobin and because
hemoglobin is confined to the erythrocytes, i.e., an indicator
of blood volume assuming a constant hematocrit. However,
a linear relationship is not to be expected because the cross-
sectional area of vessels — the Chalkley count — is a two-
dimensional parameter, whereas blood volume — the
hemoglobin concentration — is a three-dimensional
parameter. Many small, and perhaps immature, vessels
might cause a different relationship between hemoglobin
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Figure 4. Effect of continuous TNP-470 therapy on NIRS recordings and Chalkley counts in U87 (A, C ) and MLL tumors (B, D ). The final NIRS recordings and the
Chalkley counts were significantly lower in TNP -470– treated tumors (open diamond and open circle ) than controls ( solid diamond and solid circle ). Mean
value±SD, t - test.
328 Tumor Vascularity by NIRS Kragh et al.
Neoplasia . Vol. 3, No. 4, 2001
concentration and vascular density than few or larger
vessels due to differences in several parameters such as
vascular area, vessel diameter, hematocrit, and perhaps
even blood flow rate.
The NIRS instrument applied in this study is a flash
instrument.The flashoperatesat 100Hzand thepulsewidthof
the individual flash pulses is approximately 2 microseconds,
i.e., the flash is on for 200sec/seccorresponding to0.02%of
the time. The power consumption of the flash unit is 14W and
therefore, the maximal heat deposition possible is 0.003 J/
sec, corresponding to a temperature increase of 0.048C/min.
Because the individual measurements only last 5 to 10
seconds and because only a fraction of the 14-W power
consumption of the flash is converted to light, it is safe to
assume that there can be no significant heating of the tumor.
During tumor growth, angiogenesis occur to fulfil the
vascular demands of the expanding tumor [20]. Accordingly,
we found that absorbance of 800 nm light, i.e., the
hemoglobin concentration, increased with the tumor size
during early tumor growth until a tumor-specific plateau was
reached from tumor sizes of 100 to 150 mm3. This tumor
volume reflects the limited measuring volume of our
reflectance NIRS equipment because a further increase in
the tumor volume did not cause any change in the NIRS
recordings. It also reflects that in a certain tumor size range,
the ratio of the vascular volume relative to the tumor volume
remains constant. The NIRS recordings were stable at tumor
sizes from 150 to 600 mm3. Larger tumors often contain high
fractions of necrotic tissue or hemorrhages, which could
interfere with the presumed vascular hemoglobin content
[8 ]. In the present study, we used small experimental tumors
only and we found no pools of blood during dissection and
only necrosis in two of the U87 tumors during macroscopic
and histological examination. These two tumors did not co-
localize with the other U87 tumors in Figure 3. They had
lower NIRS recordings due to the necrosis not containing
hemoglobin, but similar Chalkley counts compared to the
other U87 tumors, because the Chalkley count was
estimated in non-necrotic areas only.
Assuming that angiogenesis is a growth- limiting step in
tumor growth, which is why anti -angiogenic therapy is
supposed to work, the ratio of tumor cells to vessels, i.e.,
the tumor vascularization, must remain relatively constant in
the tumors unless the demands for oxygen and nutritive
demands or the perfusion efficiency are changed. Thus,
unless the tumor cells change their metabolic phenotype
during anti -angiogenic therapy, it is likely that the vascular
density is similar in treated and untreated tumors, if the
therapy leads to growth retardation of the treated tumors. In a
previous study, a 7-day TNP-470 schedule resulted in
significant growth retardation of treated tumors, but no
alteration in Chalkley counts [19]. In the present study, we
also found significant growth retardation in tumors treated
continuously with TNP-470 compared to controls. But all
tumors started to grow during treatment and they eventually
reached the same final tumor size as the untreated controls
had done within a shorter time period. When compared at
their final sizes, a significantly lower vessel count and NIRS
recording were observed in the TNP-470–treated versus
untreated tumors. Whether this effect was due to smaller
vessel dimensions or vessel numbers is not known. But
because a reduced vascular density following continuous
TNP-470 treatment occurred in tumors that grew in spite of
therapy, this parameter is less likely to represent a measure
of anti -angiogenic effect. It rather reflects an adaptation, or
even resistance, to anti -angiogenesis, e.g., by clonal
selection or by an altered metabolic phenotype. The
apparently slower growth of treated versus untreated tumors
indicates that some phenotypic changes were induced by
continuous treatment. Whether this change reflects a
decrease in nutritive demands or tolerance towards hypoxia,
or rather a more transport efficient vascular phenotype, is not
known at present. Preliminary data seem to favor the latter
explanation [21].
We conclude that the NIRS technique provides non-
invasive measurement of the degree of vascularization in
untreated tumors and that NIRS can measure modifications
in tumor vascularization by anti -angiogenic therapy.
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